RAP-219
Drug-Resistant Focal Epilepsy
Key Facts
About Rapport Therapeutics
Rapport Therapeutics is advancing a new class of precision medicines for brain disorders by targeting specific receptor-associated proteins (RAPs) to achieve unprecedented selectivity and therapeutic windows. The company's lead candidate, RAP-219, is a GABA-A receptor-associated protein modulator in Phase 1b/2a development for drug-resistant focal epilepsy, with a broader pipeline targeting other neurological conditions. Founded by industry veterans and backed by a strong syndicate, Rapport leverages deep neuroscience expertise to address high-unmet-need disorders with its innovative platform.
View full company profileAbout Rapport Therapeutics
Rapport Therapeutics is advancing a new class of precision medicines for brain disorders by targeting specific receptor-associated proteins (RAPs) to achieve unprecedented selectivity and therapeutic windows. The company's lead candidate, RAP-219, is a GABA-A receptor-associated protein modulator in Phase 1b/2a development for drug-resistant focal epilepsy, with a broader pipeline targeting other neurological conditions. Founded by industry veterans and backed by a strong syndicate, Rapport leverages deep neuroscience expertise to address high-unmet-need disorders with its innovative platform.
View full company profile